Drug Trial Radar · NCT07899632
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Aug 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Medsyn Biopharma, LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors. The main goals of this study are to: * Find the recommended dose of MDSY-1240 that can be safely given to participants * Learn more about the side effects and effectiveness of MDSY-1240
Conditions
- Triple-Negative Breast Cancer (TNBC)
- Gastric Cancer (GC)
- Gastric Cancer Adenocarcinoma Metastatic
- Ovarian Cancer Metastatic
- Ovarian Cancer Metastatic Recurrent
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Hepatocellular Carcinoma Metastatic
- Classical Hodgkin Lymphoma Relapsed
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Cutaneous T-Cell Lymphoma/Sezary Syndrome
- Cutaneous T-Cell Lymphomas
- Peripheral T-cell Lymphoma (PTCL)
- Large Granular Lymphocytic Leukemia (LGL-L)
- T-Cell Large Granular Lymphocytic Leukemia
Interventions
MDSY-1240Drug
Participants will receive MDSY-1240 Intravenously (IV) on days 1, 8, 15, and 22 in a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days.
- Part 1 (Dose Escalation): Number of Participants With Serious Adverse Events (SAEs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
- Part 1 (Dose Escalation): Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
- Part 1 (Dose Escalation): Number of Participants With Treatment-Related Adverse Events (TRAEs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
- Part 1 (Dose Escalation): Number of Participants With Dose Interruptions Due to Adverse EventsTime frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
- Part 1 (Dose Escalation): Number of Participants With Treatment Discontinuations Due to Adverse EventsTime frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
- Part 1 (Dose Escalation): Number of Participants With Infusion-Related Reactions (IRRs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
- Part 1 (Dose Escalation): Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: During the Dose-Limiting Toxicity (DLT) evaluation period from Cycle 1 Day 1 through Day 22 of Cycle 1.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.